We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+10.06%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$278M
AUM Growth
+$69.7M
Cap. Flow
+$59.7M
Cap. Flow %
21.48%
Top 10 Hldgs %
34.47%
Holding
97
New
38
Increased
13
Reduced
9
Closed
33

Top Buys

1
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$7.55M
2
CYH icon
Community Health Systems
CYH
+$7.52M
3
CELG
Celgene Corp
CELG
+$7.17M
4
MRK icon
Merck
MRK
+$5.93M
5
SAGE
Sage Therapeutics
SAGE
+$5.16M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$6.13M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$5.28M
3
ASRT
Assertio
ASRT
+$4.83M
4
NVRO
NEVRO CORP.
NVRO
+$4.45M
5
INSY
Insys Therapeutics, Inc.
INSY
+$4.22M

Sector Composition

1 Healthcare 71.61%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
76
CALL
Stryker
SYK
$123B
– –
-100,000
Closed -$9.43M
SYK icon
77
Stryker
SYK
$123B
– –
-35,000
Closed -$3.3M
TNDM icon
78
Tandem Diabetes Care
TNDM
$1.17B
– –
-10,000
Closed -$1.27M
UHS icon
79
Universal Health Services
UHS
$9.15B
– –
-30,000
Closed -$3.34M
NVRO
80
DELISTED
NEVRO CORP.
NVRO
– –
-115,000
Closed -$4.45M
IMGN
81
CALL
DELISTED
Immunogen Inc
IMGN
– –
-300,000
Closed -$1.83M
ISEE
82
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-65,000
Closed -$2.92M
BLCM
83
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-7,500
Closed -$1.73M
AMAG
84
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-80,000
Closed -$3.41M
ACHN
85
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-150,000
Closed -$1.84M
INSY
86
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-200,000
Closed -$4.22M
HZNP
87
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-300,000
Closed -$3.87M
KITE
88
DELISTED
Kite Pharma, Inc.
KITE
– –
-60,000
Closed -$3.46M
ARIA
89
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-300,000
Closed -$2.06M
ASPX
90
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-20,000
Closed -$1.05M
SLXP
91
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
– –
-30,000
Closed -$3.45M
BDSI
92
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-175,000
Closed -$2.39M
AIRM
93
DELISTED
Air Methods Corp
AIRM
– –
-85,000
Closed -$3.74M
RPTP
94
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
– –
-150,000
Closed -$1.58M
LJPC
95
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-286,053
Closed -$5.28M
1 2 3
4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Ghost Tree Capital held 97 positions worth $278M, up 33% from $208M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ghost Tree Capital deployed $59.7M of net new capital in Q1 2015, opening 38 new positions and adding to 13 existing holdings. Its largest new stake was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Advaxis Inc, an estimated $3.06M trimmed.

  • Ghost Tree Capital's largest Q1 2015 buy was ZS PHARMA INC COMS TK (DE): 165,000 shares worth $6.94M.
  • Ghost Tree Capital added most to Allergan plc in Q1 2015, an estimated $4.99M increase.
  • Ghost Tree Capital's biggest Q1 2015 reduction was Advaxis Inc, cutting an estimated $3.06M.
  • Ghost Tree Capital fully exited Gilead Sciences in Q1 2015, selling an estimated $6.13M.
  • Ghost Tree Capital's ten largest holdings make up 34% of its $278M portfolio in Q1 2015.
  • Ghost Tree Capital opened 38 new positions and closed 33 in Q1 2015.
  • Ghost Tree Capital's portfolio value rose 33% quarter-over-quarter to $278M.

Based on Ghost Tree Capital's 13F filing for Q1 2015, filed 15 May 2015.